Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation.
about
The ubiquitin-proteasome system as a drug target in cerebrovascular disease: therapeutic potential of proteasome inhibitors.Neuroprotection in ischemia-reperfusion injury: an antiinflammatory approach using a novel broad-spectrum chemokine inhibitor.Proteasome inhibition: a new anti-inflammatory strategy.TAT-Hsp70 induces neuroprotection against stroke via anti-inflammatory actions providing appropriate cellular microenvironment for transplantation of neural precursor cellsThe potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia.The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?Selective inhibition of nuclear factor-kappaB activation after hypoxia/ischemia in neonatal rats is not neuroprotective.The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis.Proteasome and Organs Ischemia-Reperfusion Injury.Neuroprotective effect of secreted factors from human adipose stem cells in a rat stroke model.Cellular and Molecular Mechanisms Underlying Non-Pharmaceutical Ischemic Stroke Therapy in Aged Subjects.Protein Modifications with Ubiquitin as Response to Cerebral Ischemia-Reperfusion Injury.Systemic Proteasome Inhibition Induces Sustained Post-stroke Neurological Recovery and Neuroprotection via Mechanisms Involving Reversal of Peripheral Immunosuppression and Preservation of Blood-Brain-Barrier Integrity.The ubiquitin-proteasome system: a novel target for anticancer and anti-inflammatory drug research.
P2860
Q33892755-78641B11-D07B-454D-BF5F-11AB87A5EE2EQ34085987-57B8DAED-6B1D-4D3A-ABE9-EA87E3C10B0CQ35109750-C835573A-F0BD-4041-8133-9246E501AAE8Q37298275-926AD058-6EA4-45C9-877B-866E57C898EBQ37637177-D3DFD41A-1C03-4A7C-9ED7-C5ACE0752059Q38061412-029B4E1E-B5FB-49C9-B352-EDFD58FD985EQ38152513-0A524592-6C17-4464-BF1E-F7BE53804AA3Q38316406-55979293-3C56-44BF-9C30-209F8C606590Q42269178-E63B9C89-1977-4B52-B05C-8330C1390912Q47232399-E3A18911-FA3D-49CA-8011-D9DE37F8100DQ47742689-DB16D083-2DA5-4751-841E-30B90D437C7AQ47891295-56B1036B-C8F0-440E-942E-33CCBF132EFBQ47903181-36CFA7C8-73AB-49D9-9BEA-CFE7AD159A75Q48451321-596B546D-EB75-48AA-940C-A03B59F1A5A4Q53495126-3C28DD63-33B3-4E16-9799-36530F2E672F
P2860
Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-kappaB activation.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@ast
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@en
type
label
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@ast
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@en
prefLabel
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@ast
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@en
P2093
P1433
P1476
Neuroprotection achieved with ...... h blocks NF-kappaB activation.
@en
P2093
P304
P356
10.1097/00001756-200002070-00041
P577
2000-02-01T00:00:00Z